Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 13.9% After Analyst Upgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price traded up 13.9% during trading on Monday after Wedbush raised their price target on the stock from $32.00 to $34.00. Wedbush currently has an outperform rating on the stock. Sarepta Therapeutics traded as high as $24.46 and last traded at $24.0730. 1,556,026 shares were traded during mid-day trading, a decline of 47% from the average session volume of 2,936,165 shares. The stock had previously closed at $21.13.

SRPT has been the subject of several other research reports. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, January 14th. Bank of America raised their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research report on Wednesday, October 22nd. Wall Street Zen downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Robert W. Baird dropped their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of “Hold” and a consensus price target of $33.84.

Insider Activity

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.60% of the company’s stock.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: EMBARK 3‑year topline: ELEVIDYS showed statistically significant, clinically meaningful slowing of Duchenne progression on key functional measures versus an untreated external control — the primary catalyst cited by press releases and company materials. Sarepta Announces Positive Topline Three-Year EMBARK Results
• Positive Sentiment: Wide media and analyst pickup is amplifying the move: Reuters, Barron’s and trade outlets flagged sustained motor‑function benefit at three years, driving buying interest and heavier volume. This broad coverage helps investor confidence in the durability of Elevidys’ effect. Reuters: Sarepta’s Duchenne gene therapy helps maintain motor function
• Positive Sentiment: Broker upgrade: Zacks moved SRPT to a Buy (Zacks Rank #2), reinforcing short‑term optimism and potentially attracting more momentum traders and fund buying. Zacks: Sarepta Therapeutics Upgraded to Buy
• Neutral Sentiment: Conference call/transcript and broader analyst reads available — investors can review the Seeking Alpha transcript and company commentary for granularity on endpoints, subgroup results, and safety. These details will shape longer‑term views but are primarily confirmatory for now. Seeking Alpha: EMBARK 3‑Year Transcript
• Negative Sentiment: Regulatory/safety overhang remains: FDA previously restricted Elevidys to ambulatory patients following acute liver‑failure deaths in non‑ambulatory patients — that history keeps a regulatory risk premium on the stock and narrows the commercial patient population. Investors should watch follow‑up safety data and labeling/regulatory commentary. Blockonomi: Investors Brace for Pivotal Data Release
• Negative Sentiment: Financial/operational context: Sarepta has shown revenue weakness y/y and a recent quarterly EPS miss; the business remains unprofitable on margin and ROE metrics, so positive clinical news may not fully remove execution and commercial risks. (Review company filings and recent results for details.)

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. iSAM Funds UK Ltd purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $25,000. Ancora Advisors LLC increased its stake in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the third quarter valued at about $33,000. Allworth Financial LP lifted its position in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $21.22 and a two-hundred day moving average price of $19.83. The stock has a market cap of $2.39 billion, a P/E ratio of -7.57, a price-to-earnings-growth ratio of 0.52 and a beta of 0.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The business had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. During the same period last year, the business posted $0.62 EPS. The firm’s revenue for the quarter was down 14.5% compared to the same quarter last year. On average, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.